Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sequenom IPO Prospectus Shows Diagnostics Potential In Product Pipeline

This article was originally published in The Gray Sheet

Executive Summary

Potential applicability of Sequenom, Inc.' s industrial genomics technology to the field of diagnostics is outlined in a preliminary prospectus for an initial public offering of up to $70 mil. in common stock, recently filed with the Securities and Exchange Commission.

You may also be interested in...



Sequenom

Development stage industrial genomics firm grosses $157 mil. in initial public offering of approximately 6 mil. shares at $26 per share on Feb. 1, including 787,500 overallotment shares. San Diego-based Sequenom outlined plans for the offering late last year (1"The Gray Sheet" Dec. 13, p. 19). The proceeds will be used for expansion of sales, customer support and facilities, as well as continued product development, R&D, debt repayment and other general corporate purposes. The stock trades on the Nasdaq exchange under the symbol "SQNM." Underwriters included Warburg Dillon Read, Robertson Stephens and SG Cowen

Sequenom

Development stage industrial genomics firm grosses $157 mil. in initial public offering of approximately 6 mil. shares at $26 per share on Feb. 1, including 787,500 overallotment shares. San Diego-based Sequenom outlined plans for the offering late last year (1"The Gray Sheet" Dec. 13, p. 19). The proceeds will be used for expansion of sales, customer support and facilities, as well as continued product development, R&D, debt repayment and other general corporate purposes. The stock trades on the Nasdaq exchange under the symbol "SQNM." Underwriters included Warburg Dillon Read, Robertson Stephens and SG Cowen

Caliper's $46 Mil. IPO To Fund LabChip Manufacturing Scale-Up, R&D

Development of "lab-on-a-chip" technologies used in high-throughput nucleic acid analysis for diagnostics applications is one of several development projects that would benefit from Caliper Technologies' $46 mil. initial public offering.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel